Phase II evaluation of pyrazofurin in patients with carcinoma of the lung

R. J. Gralla, V. E. Currie, R. E. Wittes, R. B. Golbey, C. W. Young

Research output: Contribution to journalArticlepeer-review

12 Scopus citations


Thirty-one patients with lung cancer were entered in a weekly phase II trial of iv pyrazofurin (PZF). Dose-limiting side effects included mucositis and hematologic toxicity primarily manifested as anemia. Major therapeutic activity did not occur in the patients entered in this trial. The authors conclude that PZF has little therapeutic value as a single agent in this dose schedule in previously treated patients with advanced lung cancer. Although this trial was conducted on pretreated patients, their general condition permitted outpatient management. In addition, the median survival time of the group from the beginning of therapy was 5 months which is comparable to the survival time in some groups receiving initial chemotherapy.

Original languageEnglish (US)
Pages (from-to)451-452
Number of pages2
JournalCancer Treatment Reports
Issue number3
StatePublished - Dec 1 1978

ASJC Scopus subject areas

  • Oncology
  • Cancer Research


Dive into the research topics of 'Phase II evaluation of pyrazofurin in patients with carcinoma of the lung'. Together they form a unique fingerprint.

Cite this